Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesLSE:RUA +4.35%47 PB Ratio is 2.12 as of Jul. 26, 2026, which is 33% above its 10-year median of 1.59. GuruFocus rates LSE:RUA with a GF Score™ of 47/100 and a GF Value™ of £0.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 52.28% on this metric.
RUA Life Sciences PLC stock PB Ratio (=2.12) is close to 3-year high of 2.12.
The historical rank and industry rank for RUA Life Sciences's PB Ratio or its related term are showing as below:
LSE:RUA'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.59 Max: 11.14
Current: 2.12
During the past 13 years, RUA Life Sciences's highest PB Ratio was 11.14. The lowest was 0.43. And the median was 1.59.
LSE:RUA's PB Ratio is ranked worse than 52.28% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.005
vs LSE:RUA: 2.12
During the past 12 months, RUA Life Sciences's average Book Value Per Share Growth Rate was -11.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -4.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of RUA Life Sciences was 255.70% per year. The lowest was -50.40% per year. And the median was -8.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RUA Life Sciences PB Ratio Related Terms
RUA Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RUA Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RUA Life Sciences (LSE:RUA) has a PB Ratio of 2.12 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RUA Life Sciences and its competitors. This is 33% above median its historical median of 1.59. Over the past decade, RUA Life Sciences' PB Ratio has ranged from 0.43 to 11.14. According to the industry distribution chart, RUA Life Sciences ranks #412 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 52.3%.
Is RUA Life Sciences' PB Ratio too high?
RUA Life Sciences' current PB Ratio of 2.12 is 33% above median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 11.14. The Medical Devices & Instruments industry median PB Ratio is 2.01. RUA Life Sciences' value of 2.12 is 5.7% above this industry median. Based on the distribution chart, RUA Life Sciences ranks #412 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #412 out of 788 companies for PB Ratio. This places RUA Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.01. RUA Life Sciences' value of 2.12 is 5.7% above this benchmark. Historically, RUA Life Sciences' own PB Ratio has ranged from 0.43 to 11.14 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 2.01, RUA Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.01, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current PB Ratio of 2.12 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current PB Ratio is 2.12, which is 33% above median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.17, compared to a current price of £0.24 — trading 41.2% above its estimated fair value. The current PB Ratio is 2.12, which is 33% above median its 10-year median of 1.59 and 5.7% above the Medical Devices & Instruments industry median of 2.01. RUA Life Sciences' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current PB Ratio is 2.12 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of £0.24 is trading 41.2% above its estimated GF Value™ of £0.17.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for LSE:RUA:
PB Ratio: 2.12 (33% above median its 10-year median of 1.59)
GF Value™: £0.17 vs. price of £0.24 (41.2% above fair value)
Industry Position: 5.7% above the Medical Devices & Instruments median (#412 of 788)
No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
47GF Score
Get the complete analysis for LSE:RUA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RUA has been successfully added to your 
